

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNUAL GENERAL MEETING HELD ON 18 MAY 2018 – POLL RESULTS

The Company is pleased to announce that all the resolutions set out in the notice of AGM and proposed at the AGM were duly passed by the shareholders of the Company by way of poll at the AGM.

China Resources Pharmaceutical Group Limited (the “**Company**”) is pleased to announce the poll results in respect of the resolutions proposed at the annual general meeting (the “**AGM**”) of the Company held on 18 May 2018 as follows:

Ordinary Resolutions proposed at the AGM		Number of Votes (%)	
		For	Against
1.	To receive and consider the audited financial statements, the directors’ report and the independent auditor’s report of the Company for the year ended 31 December 2017.	5,373,094,109 (99.99%)	500 (0.01%)
The resolution was duly passed as an ordinary resolution.			
2.	To declare a final dividend of HK\$0.11 per share for the year ended 31 December 2017.	5,373,912,009 (99.99%)	100 (0.01%)
The resolution was duly passed as an ordinary resolution.			

Ordinary Resolutions proposed at the AGM		Number of Votes (%)	
		For	Against
3.	(1) To re-elect Mr. SONG Qing as Director.	5,367,154,109 (99.87%)	6,757,000 (0.13%)
The resolution was duly passed as an ordinary resolution.			
	(2) To re-elect Mr. WANG Chenyang as Director.	Not Applicable <i>Note</i>	
	(3) To re-elect Mr. KWOK Kin Fun as Director.	5,372,564,609 (99.97%)	1,347,500 (0.03%)
The resolution was duly passed as an ordinary resolution.			
	(4) To re-elect Mr. ZHANG Kejian as Director.	5,372,564,609 (99.97%)	1,347,500 (0.03%)
The resolution was duly passed as an ordinary resolution.			
	(5) To authorise the Board to fix the remuneration of the Directors.	5,214,766,305 (98.53%)	77,642,104 (1.47%)
The resolution was duly passed as an ordinary resolution.			
4.	To appoint Ernst & Young as the independent auditor of the Company and to authorise the Board to fix their remuneration.	5,373,099,109 (99.98%)	813,000 (0.02%)
The resolution was duly passed as an ordinary resolution.			
5.	Ordinary Resolution in item No. 5 of the Notice of AGM (To give a general mandate to the Directors to buy back shares of the Company).	5,373,703,509 (99.99%)	208,600 (0.01%)
The resolution was duly passed as an ordinary resolution.			
6.	Ordinary Resolution in item No. 6 of the Notice of AGM (To give a general mandate to the Directors to issue new shares of the Company).	4,866,073,385 (90.55%)	507,838,724 (9.45%)
The resolution was duly passed as an ordinary resolution.			
7.	Ordinary Resolution in item No. 7 of the Notice of AGM (To extend the general mandate to be given to the Directors to issue new shares of the Company).	4,875,864,945 (90.73%)	498,047,164 (9.27%)
The resolution was duly passed as an ordinary resolution.			

Note: Mr. WANG Chenyang has informed the board of directors of the Company that, due to other work allocation by the Beijing State-Owned Capital Operations and Management Centre, he would not offer himself for re-election as a non-executive Director upon rotational retirement at the AGM. The ordinary resolution number 3(2) as set out in the Notice of AGM has been withdrawn from voting at the AGM. Please refer to the announcement of the Company dated 16 May 2018 for detail.

As at the date of the AGM, the total number of issued and fully paid up shares of the Company was 6,284,506,461 shares. In relation to all resolutions proposed at the AGM, the total number of shares entitling the holders to attend and vote for or against the resolutions at the AGM was 6,284,506,461 shares. There were no shares entitling the holders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and there were no shares requiring the holders to abstain from voting at the AGM under the Listing Rules. No shareholders of the Company have stated their intention in the circular of the Company dated 18 April 2018 (the “**Circular**”) to vote against or to abstain from voting on any of the proposed resolutions at the AGM.

Tricor Investor Services Limited, the Share Registrar of the Company, acted as scrutineers for the vote-taking at the AGM.

Shareholders may refer to the Circular for details of the above resolutions proposed at the AGM. The Circular may be viewed and downloaded from the Company’s website at www.crpharm.com or the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk.

CHANGE OF DIRECTOR

Reference is made to the announcement dated 16 May 2018 in relation to Mr. WANG Chenyang’s (“**Mr. WANG**”) retirement. Due to other work allocation by the Beijing State-Owned Capital Operations and Management Centre, Mr. WANG would not offer himself for the re-election as a non-executive Director upon rotational retirement at the AGM. Mr. WANG has confirmed that he has no disagreement with the Board and that there is no matter relating to his retirement that needs to be brought to the attention of the Shareholders.

The Board would like to express its appreciation and gratitude to Mr. WANG for his valuable contribution to the Company during his tenure of office.

For and on behalf of
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Executive Director

Hong Kong, 18 May 2018

As of the date of this announcement, the Board comprises Mr. FU Yuning as chairman and non-executive Director, Mr. WANG Chuncheng, Mr. SONG Qing and Mr. LI Guohui as executive Directors, Mr. CHEN Rong, Mr. YU Zhongliang and Ms. WANG Jing as non-executive Directors, Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.